Prescription Based Pharmaceutical Products from Cannabis
InMed turns ingredients from cannabis plants into prescription based pharmaceutical products.
InMed is a biopharmaceutical company that specializes in the discovery and development of novel, cannabinoid-based therapeutics for the treatment of diseases with high unmet medical need.
InMed employs a highly scientific approach to designing and developing medicines, which will help unlock the full potential of cannabinoid pharmaceuticals. One proprietary technology is our bioinformatics platform, which uses a computer-based drug candidate selection process to reach high-probability conclusions from massive, publicly available databases together with an internal library of cannabinoid drug information.
InMed is also developing a robust, high-yield, microbial-based biosynthesis process designed to enable the manufacturing of the multitude of cannabinoids (90+) found from natural sources. InMed’s products are designed to be bio-identical to the naturally-occurring cannabinoids and the process envisioned to offer cost and time savings, and superior ease, control and quality of manufacturing when compared to alternative methods.
The majority of pharmaceutical and academic research & development activities investigating the physiological and disease fighting properties of cannabis revolves around the understanding of one class of biologically active ingredients, the cannabinoids. In the 1960s, several interesting compounds were isolated from the cannabis plant. While there are over 90 different cannabinoids, the two most well-known and studied compounds in the cannabis plant also happen to be the two that occur in the largest quantity: Δ9-tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”).
Referenced financial figures as of June 30, 2018; please refer to www.sedar.com for complete full financial statements.
For more information on InMed Pharmaceuticals (IN:TSX, IMLFF:OTCQX) please fill out the form below.